|
||
Articles |


Laboratory of Immunology, Korea Cancer Center Hospital, Seoul 139-240, Korea; and the
Department of Molecular Biology, Dankook University, Seoul 140-714, Korea
| Abstract |
|---|
|
|
|---|
Progenitor T cells arise in the bone marrow and migrate to thymus, where they continue to develop. During the T cell development, more than 95% of developing immature thymocytes die by apoptosis as a consequence of negative selection or lack of positive selection (1). This apoptotic death targets mainly the cortical double-positive (CD4+CD8+) thymocytes. In thymocytes, apoptosis can be triggered by several exogenous stimuli such as glucocorticoids (2–4), removal of growth factors (5, 6), exposure to
GCs, when complexed with an activated receptor, can induce or inhibit the expression of specific genes, which may be related to the induction of apoptosis. The transcriptional regulation of downstream genes by GCs requires not only GR itself but several additional transcription factors such as the SWI–SNF protein complex (16–20). For example, the rat GR, when expressed in yeast, requires SWI–SNF proteins for transcriptional activation of GR-responsive genes and the GR–SWI3 complexes were coimmunoprecipitated in yeast extract (19, 20). In addition, antibodies against SWI3 interfere with the ability of rat GR to activate transcription in Drosophila melanogaster nuclear extracts (19).
SWI3 is a subunit of the SWI–SNF complex that seems to facilitate transcriptional activation by antagonizing the repressive actions of chromatin (21–23). The other subunits of the SWI–SNF complex so far identified include the SWI1 (ADR6), SWI2 (SNF2), SNF5, SNF6, SNF11, and SWP73. The complex was initially identified in Saccharomyces cerevisiae (S. cerevisiae) as a positive regulator of HO, a gene involved in mating type switching (24, 25), and SUC2, a glucose-repressible gene that encodes the enzyme invertase (26, 27). These SWI gene products were subsequently found to be required for the transcriptional activation of many other genes (28–31). Such activities of the SWI–SNF proteins are closely interconnected and they seem to function as components of a complex that associates with genespecific activators (31–35). The functional significance of the SWI–SNF complex is reflected by the evolutionary conservation of these genes in higher eukaryotes. Several higher eukaryotic homologues of SWI–SNF genes such as Drosophila homeotic gene activator brm, hbrm (also known as hSNF2
In this paper, we describe a newly isolated mouse gene, the SWI3-related gene (SRG3), expressed in thymus and encoding a protein that shows significant amino acid sequence homology to both yeast SWI3 and human BAF155 proteins. The SRG3 protein coimmunoprecipitates with a mouse SWI2-like protein, suggesting their forming a protein complex in vivo. In addition, our data show that the SRG3 is expressed at much higher level in thymus than in peripheral lymphocytes. Because the GC is proposed to be a regulatory molecule in thymocyte development in thymus, and the SWI-related proteins have an important role in GC-mediated gene regulation, the high level expression of SWI3-related gene (SRG3) in thymocytes may imply that SRG3 has a crucial role in thymocyte development as a mediator of GC-induced transcriptional activation and apoptotic cell death of thymocytes. As a first step of testing this hypothesis, we analyzed the effect of downregulation of SRG3 expression in a GC-sensitive thymoma cell line on GC-induced apoptosis.
Isolation and Purification of Poly(A)+ RNA.
Preparation of Subtractive Probe.
DNA Sequencing and Computer Analysis.
Separation of T and B Cell.
Overexpression and Purification of GST–fusion Protein.
Immunoprecipitation and Immunoblot Analysis.
Complementation of Yeast swi3– Mutant.
Preparation of the Glycerol Density Gradient Sedimentation Fraction from Thymocytes Extract.
Construction of a Plasmid Expressing Anti-sense RNA of the SRG3 Gene.
Induction and Measurement of Apoptosis.
-irradiation (7), and antigen binding involving the CD3/ TCR (8–10). The effect of glucocorticoids (GCs)1 is selective; the immature CD4+CD8+ thymocyte fraction is rapidly killed by GC treatment, whereas both the precursor population (TCR–CD4–CD8–) and mature thymocytes (CD4+ or CD8+) are relatively resistant (11). It was reported that GC is produced within the thymus (12), and that transgenic expression of anti-sense RNA to glucocorticoid receptor (GR) significantly affects the thymocyte development (13). These results suggest that endogenous GC produced in thymus may participate as an important regulatory molecule of normal thymic development (14, 15).
) and BRG1 (also known as hSNF2β) have been identified (36–39). In addition, a human protein homologue of SNF5 (40, 41) and mouse BAF60 (42), which is homologous to SWP73, have been identified. Recently, distinct complexes containing the BRG1 or hbrm that have an in vitro activity similar to yeast SWI–SNF have been purified from human cell lines (42, 43). From these complexes, the human BAF155 and BAF170 proteins that are homologous to SWI3 protein were identified (42).
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Mice and Cells.
C57BL/6J mice were maintained in the Institute for Molecular Biology and Genetics (Seoul National University, Seoul, Korea). The yeast strain CY165 (MAT
, swi3
:: trp1-
1, HO–lacZ, ura3-52, leu2-
1, his3-
200, ade2-101, lys-801) cells, and yCP50 plasmid containing the SWI3 gene were gifts from C. Peterson (University of Massachusetts, Worcester, MA). Yeast cells were grown in synthetic minimal medium (0.67% Bactoyeast nitrogen base without amino acids; GIBCO BRL, Gaithersburg, MD) supplemented with leucine, histidine, adenine, and lysine to a mid-log phase. The mouse thymoma cell line, S49.1, was purchased from American Type Culture Collection (ATCC, Rockville, MD) and grown in DMEM supplemented with 10% fetal bovine serum.
Total RNA was isolated by CsCl banding, as described by Chomczynski and Sacchi (44). Intact thymi and spleens were collected from 3-5-wk-old mice and used as sources for RNA. Poly(A)+ RNA was isolated by oligo(dT)–cellulose chromatography (45).
10 µg of poly(A)+ RNA was heated at 65°C for 2 min and annealed with 1 mg of magnetic beads containing oligo (dT) (Dynabeads oligo [dT]25; Dynal, Inc., Great Neck, NY) for 30 min at room temperature (46). The annealed poly(A)+ RNA was separated in magnetic field, and used as templates for the synthesis of the first-strand cDNA. The second-stranded cDNA was synthesized by random priming using hexanucleotides and 200 µCi of [
-32P]dCTP (3,000 Ci/mmol). To prepare a subtractive probe, 200 µg of the first-stranded spleen cDNA conjugated with magnetic beads were mixed with the labeled probe. After incubating at 55°C for 1 h, the labeled probe DNAs hybridized to the first-stranded spleen cDNA were removed using magnetic field, and the remaining subtractive probe was used for the screening of thymic cDNA library. The cDNA library was obtained from M.M. Davis at Stanford University (Stanford, CA).
To determine the nucleotide sequences, the restriction fragments of the cloned gene were subcloned into pBluscript (SK–) vector (Stratagene Inc., La Jolla, CA). Nested deletions were generated by the Erasea-Base system (Promega Corp., Madison, WI). The nucleotide sequence was determined by dideoxy chain termination method (47) using Sequenase 2.0 kit (United States Biochemical Corp., Cleveland, OH). Homology searches of the nucleotide and deduced amino acid sequences with sequences were performed at the National Center for Biotechnology Information, using the BLAST network service (48).
Single cell suspensions were prepared from intact spleens and lymph nodes of C57BL/6J mice. After the red blood cells were removed, cells were resuspended in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3). To isolate T cells, single cell suspensions were sequentially reacted with biotinylated H57-597 antibody, which is specific to
β TCR, and streptavidin-conjugated microbeads. The B cells were reacted with microbead-conjugated goat anti– mouse IgM. The cell-magnetic bead conjugates were separated by a magnetic cell sorter (MACS; Miltenyi Biotec, GmbH, Bergisch Gladbach, FRG) (49). The purity of isolated populations were confirmed by FACS® (Becton Dickinson, Mountain View, CA) analysis and Northern blot assay using TCF-1, a T cell–specific gene, as a probe.
For the construction of GST–fusion protein, COOH-terminal region of the SRG3 gene was inserted into pGEX4T-2 vector in frame. DH5
cells harboring recombinant plasmids with GST–3C fusion were grown overnight and diluted to 1:200 in 200 ml of LB medium. After incubation at 37°C for 2 h with vigorous shaking, the culture was treated with 1 mM IPTG and then incubated for 3 h to induce expression of the fusion protein. Cells were harvested and resuspended in a sample loading buffer (50 mM Tris–HCl, pH 6.8, 100 mM DTT, 4% SDS, 0.2% BPB, 20% glycerol), and boiled for 2 min. These lysates were analyzed by electrophoresis on polyacrylamide gel. The overexpressed protein was purified by glutathion–sepharose 4B affinity chromatography as described by Smith and Johnson (50). The polyclonal antiserum was prepared by immunizing New Zealand white rabbit with the purified fusion protein.
The immunoprecipitation of the SRG3 and SWI2-like protein was performed by a method described by Muchardt et al. (40) with some modifications. The single cell suspension of the mouse thymus was harvested in immunoprecipitation (IP) buffer (20 mM Hepes, pH 7.6, 10% glycerol, 25 mM MgCl2, 0.1 mM EDTA, 0.2% NP-40) containing 0.1 M potassium acetate and 2.25 µg/ml pepstatin, 10 µg/ml leupeptin, 1 µg/ml soybean inhibitor, 2 mM PMSF, and 0.1 mM DTT. The cells were sonicated and debris were pelleted by centrifugation. The extracts were precleared with protein A–sepharose suspension and anti-SRG3 or anti-hSWI2 rabbit antiserum were added. After overnight incubation at 4°C, the extracts were incubated with protein A–sepharose suspension. The beads were washed three times in IP buffer containing 0.6 M potassium acetate, and once with IP buffer without Hepes. The precipitate was eluted by boiling in SDS-PAGE loading buffer. For immunoblot analysis, the proteins separated on SDS-PAGE were electrotransferred to nitrocellulose paper, and incubated in blocking solution (3% non fat dry milk, 50 mM Tris–HCl, pH 7.5, 150 mM NaCl) with gentle agitation for 2 h. After the blot was incubated with the SRG3 antiserum or hSWI2 antiserum, the specific bands were detected by treating the blot with anti-rabbit IgG conjugated with alkaline phosphatase in blocking solution (100 mM Tris–HCl, pH 9.5, 100 mM NaCl, 10 mM MgCl2) containing 165 µg/ml BCIP and 330 µg/ml NBT.
For complementation study, the SWI3–SRG3 hybrid gene encoding the NH2-terminal part of SWI3 and the COOH-terminal part of SRG3 was synthesized. The full-length SRG3 gene or the SWI3–SRG3 hybrid gene were inserted into the pRS316GU vector containing the URA3 promoter and the URA3 gene as auxotrophic marker. The resulting constructs were used to transform CY165 yeast cells that harbor swi3– mutation and the HO–lacZ fusion gene construct. The Ura+ cells were cultured in synthetic minimal media. Cells were collected when OD595 of the culture reached 0.5. β-gal assay was performed as described by Breeden and Nasmyth (51). The Cp15 construct that contains the SWI3 gene in yCP50 vector was also used to transform CY165 cells as a positive control.
The thymocytes were prepared as a single cell suspension from thymi and homogenized in 700 µl extraction buffer (40 mM Hepes, pH 7.3, 200 mM NaCl, 0.5 mM DTT, 2 mM EDTA, and 2.25 µg/ml pepstatin, 10 µg/ml leupeptin, 1 µg/ml soybean inhibitor). After centrifugation at 12,000 rpm for 20 min at 4°C, the supernatant containing 7.2 mg of total protein in 400 µl was layered on the top of linear 18–40% 10 ml glycerol gradient cushion containing 40 mM Hepes, pH 7.3, 200 mM NaCl. After ultracentrifugation at 36,500 rpm in Beckman SW41 rotor for 20 h at 4°C, the samples were collected from the bottom of the tube by fractionation into 33 tubes. These fractionated samples were analyzed by immunoblotting with SRG3 or hSWI2 antiserum.
A 2.8 kb XbaI fragment spanning 60 bases of 5'-untranslated region and 2772 bases of the SRG3 coding sequence was inserted into the pRc/CMV vector (Invitrogen, San Diego, CA) in the anti-sense orientation. The resulting plasmid was designated as pRcASRG3. The plasmid construct, pRcASRG3, or pRc/CMV was transfected into S49.1, a thymoma cell line (ATCC), by electroporation. The transfected cells were selected and maintained with 1 mg/ml Geneticin (GIBCO BRL, Gaithersburg, MD) in DMEM supplemented with 10% fetal bovine serum.
The apoptotic cell death of thymoma cells were induced by treatment with 10 µM hydrocortisone (Sigma Chem. Co., St. Louis, MO) for 72 h at 37°C. After hydrocortisone treatment, the cells were harvested and lysed in lysis buffer (10 mM EDTA, 50 mM Tris–HCl, pH 8.0, 0.5% sodium lauryl sarcosine) containing the 100 µg/ml proteinase K at 55°C for 2 h. The DNA was extracted with phenol/chloroform and precipitated with ethanol. After RNA was removed by RNAse A treatment, the DNA was analyzed in agarose gel electrophoresis to visualize the fragmented DNA. The apoptotic cell death was also measured by flow cytometry as described by Nicoletti et al. (52). In brief, the harvested cells were fixed with 70% ethanol and stained with 50 µg/ml of propidium iodide (PI) and 10 µg/ml RNAse A for 30 min at 4°C. After washing with PBS buffer, stained cells were analyzed using the FACStar® (Becton Dickinson, Mountain View, CA) for the DNA content.
![]()
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
Cloning and Characterization of the Mouse SWI3-related Gene (SRG3).
We made an attempt to isolate genes that are specifically expressed in thymus but not in spleen by subtractive hybridization. One of the clones isolated was found to be expressed preferentially in thymus and was found to have similar amino acid sequences to a part of SWI3 protein of S. cerevisiae. The isolated gene has an open reading frame of 3,300 bp encoding 1,100 amino acids (Fig. 1). The homology search in the GenBank sequence database of NCBI using the BLASTP program showed amino acid sequence similarity to the SWI3 protein of S. cerevisiae (Fig. 2). The new gene was named as SRG3 to emphasize its relatedness to SWI3 gene.
|
|
Recently, the human homologues of yeast SWI3, BAF155, and BAF170, were identified and designated as BRG1 associated factors (42). We found that the SRG3 protein has very high amino acid sequence homology to BAF155 protein (Fig. 2). They show 91% identity in their complete amino acid sequences, with the major deviations occurring at the NH2 termini. Therefore, we conclude that the SRG3 protein is the murine counterpart of human BAF155 protein. The SRG3 protein also matches well with the BAF170, another human SWI3 homologue; they are 60% identical and 70% similar at the amino acid level. In addition, the SRG3 protein has a considerable homology with the yeast YFK7 protein, which is also known as SWI3b (42) (Fig. 2).
The major similarity between the SWI3 and its mammalian homologues at the amino acid level is found over three regions (Fig. 2 B). The three regions of the SWI3 and SRG3 proteins shows 33–47% identity and 61–64% similarity. The NH2-terminal part of the SWI3 is also extremely acidic, yet similarity with the SRG3 is still very low. The leucine-zipper motifs in the region III of these proteins are different from SWI3 in that the third leucine of the SWI3 protein is replaced by phenylalanine in SRG3 and BAF155 (Fig. 2 C). In the COOH-terminal region, SWI3 lacks proline- and glutamine-rich regions found in its mammalian homologues. The data suggests that these proteins have similar protein structures and probably similar biochemical functions. However, there is divergence in structure and, probably, also in function between these proteins.
Identification of the SRG3 Gene Product.
To identify the protein product of the SRG3 gene, polyclonal antibody was produced against the SRG3–GST fusion protein. The COOH-terminal part of the SRG3 gene was inserted inframe into the pGEX4T-2 plasmid containing the glutathione-S-transferase (GST) gene. The overexpressed GST– 3C fusion protein with
85 kD of molecular mass was used to immunize rabbits through subcutaneous injection. After primary and booster injections, polyclonal antiserum against GST–3C fusion protein was obtained. The antiserum was confirmed to recognize specifically the fusion protein (data not shown). To identify the SRG3 gene product, immunoblot analysis was performed with crude extracts prepared from thymus and lymph node. As shown in Fig. 3 A, two bands of
155 and 170 kD were observed; the 155-kD protein is likely to be SRG3. This is supported by the observations that the protein matches well to the size of the BAF155 in human (42), that the antiserum immunoprecipitates the 155-kD protein (Fig. 3 B), and that the intensity of the 155-kD protein band was specifically reduced when anti-sense RNA to the SRG3 is expressed in a cell line (see Fig. 6 A). The antiserum also recognized a 170-kD protein that seemed to be similar to the SRG3 protein in its structure. Considering the results of human SWI3 homologues (42), it is likely that the 170-kD protein may be the mouse counterpart of the human BAF170 protein. The SRG3 and BAF170 are quite similar to each other over regions I (86%), II (93%), and III (89%) (see Fig. 2 B), and anti-SRG3 antiserum seems to recognize a murine BAF170like protein as well as SRG3. Interestingly, SRG3 is expressed at a three times higher level in thymus than in lymph nodes; however, the 170-kD protein is expressed at similar levels in both tissues.
|
|
195 kD in thymocyte extract (Fig. 3 B). The 195-kD protein is similar to the size of hSWI2 (43) and seems to be a mouse homologue of hSWI2. When thymocyte extract was immunoprecipitated with the SRG3 antiserum and blotted with the hSWI2 antiserum, a specific band corresponding to the mouse SWI2like protein was detected (Fig. 3 B, top). These results suggest that the SRG3 associates with a SWI2-like protein and possibly with other SWI–SNF proteins.
The SRG3 Protein Does Not Complement the Yeast swi3– Mutant.
To test the possibility that the mouse SRG3 gene product complements the yeast swi3– mutation, the S. cerevisiae host strain CY165 (swi3–) containing the HO–lacZ gene (25) was transformed with the pRS316GU vector containing the SRG3 full coding sequence or SWI3–SRG3 hybrid gene at the downstream of the URA3 promoter. Cells transformed with the SWI3–SRG3 hybrid gene were confirmed to express the hybrid protein by Western blotting using the SRG3 and SWI3 antisera (data not shown). The growth rate of swi3– mutant was very slow (33) and was not significantly changed after the transformation with either the SRG3 or the SWI3–SRG3 hybrid. In addition, expression of lacZ gene, controlled by the HO promoter which requires the SWI–SNF protein complex for transcriptional activation, was not induced after the transformations of SRG3 or SWI3–SRG3 hybrid. The level of expression of lacZ gene in the SRG3 transformant was only
22% of the mutant cells transformed with the yeast SWI3 (a positive control), whereas the LacZ expression level in mutant cells transformed only with a vector plasmid was
20% of the SWI3 transformed cells. The result was consistent in three independent experiments.
The SRG3 mRNA Is Expressed Highly in Thymocytes, Brain, and Testis.
Northern blot analysis of SRG3 gene expression showed that the transcripts of this gene were 3.5 and 5 kb in size (Fig. 4 A). It seems that the 5.0-kb mRNA encodes the SRG3 protein because the 3.5-kb mRNA is not long enough to include the 3,300-base open reading frame, 5'- and 3'-untranslated regions, and poly(A) tail. At this point, it is not clear what the 3.5-kb mRNA species encodes for. However, when a 1.5-kb PstI fragment from the 3'-end of the SRG3 gene was used as a probe, only the 5-kb transcript was detected (data not shown), suggesting the possibility that these two transcripts are different at their 3' termini. The SRG3 gene is expressed at higher levels in thymus, brain, and testis than in other tissues (Fig. 4 A). Northern blot analysis with RNAs isolated from separated splenic T and B cell populations showed that the two populations express similar level of SRG3. The separated population was highly pure, as judged by the Northern blot using TCF-1 gene, a T cell–specific gene (55, 56), as a probe (Fig. 4 B) and by FACS® analysis (data not shown). Interestingly, however, the level expressed in each peripheral lymphocyte population was only about 20% of that expressed in thymocytes (Fig. 4 B), as it was similarly shown by Western blot analysis (see Fig. 3 A).
|
|
50 and 30% SRG3 protein of the vector transfectants, respectively. The DNA fragmentation induced by GC treatment was greatly reduced in these clones and this effect was more dramatic in clone B, which expressed lower level of SRG3 protein than clone A (Fig. 6 B). The reduction in apoptotic cell death of the pRcASRG3 transfectants was also confirmed by FACS® analysis of the DNA contents of the cells. After GC treatment, about 46% of the vector transfectants were subdiploid and apoptotic (Fig. 6 C, c); however, only about 4% of the treated clone B transfectants were apoptotic (Fig. 6 C, d). These results suggest that the SRG3 protein is involved in the GC-induced apoptosis of the thymoma cell line. | Discussion |
|---|
|
|
|---|
In yeast, the rat GR can activate transcription from a promoter bearing the GR-responsive element in the presence of glucocorticoid (GC) (57, 58). It has been reported that transcriptional activation by GR, which regulates the expression of a network of genes in a tissue-specific manner, is dependent on SWI1, SWI2, SWI3, SWP73 gene functions in yeast (19, 59). Furthermore, SWI3 was coimmunoprecipitated with GR in yeast extracts (19), suggesting that the two proteins interact directly upon activation of GR. Our study showed that SRG3 was highly expressed in developing thymocytes compared with mature peripheral T and B lymphocytes (Fig. 3). When the level of SRG3 protein was reduced to
50–30% of normal level of thymoma cells by expressing anti-sense RNA to the gene, apoptosis induced by GC on these cells was significantly reduced (Fig. 6). These results indicate that SRG3 is required for GC-induced apoptosis in the thymoma cells and suggests that SRG3 is an important factor for GC-mediated regulation of thymocyte development.
It has been hypothesized that GC might affect thymocyte development in a number of ways. Thymocytes respond to GC by apoptosis both in vitro and in vivo (2, 60). In vivo, the immature CD4+CD8+ thymocyte population is rapidly killed in the presence of GC, whereas both the CD4–CD8– precursor population expressing no TCR– and mature thymocytes (CD4+ or CD8+) cells expressing high levels of TCR are relatively resistant. Using anti-CD3 monoclonal antibodies as a model for negative selection, it has been found that pretreatment of mice with a GR antagonist, RU486, protects immature CD4+CD8+ thymocytes from apoptosis (61). Furthermore, it has been reported that radioresistent thymic epithelial cells constitutively produce GC (12). Thus, GC and GR may function as important regulators in normal thymic differentiation (14, 15). At this point, it is not clear whether GC-induced apoptosis of thymoma cells requires SRG3 as a component of the SWI– SNF complex or as a separate entity. In yeast, transcriptional activation by GR is blocked by disrupting any one of SWI1, SWI2, and SWI3 genes, suggesting the possibility that the SWI–SNF complex is required for the GC sensitivity of thymocytes. However, it is noteworthy that SRG3 protein is expressed at a much higher level in thymocytes than in peripheral T lymphocytes and that the major part of SRG3 protein may exist independently of the SWI–SNF complex in thymus. Furthermore, even though the antisense RNA expression reduced the level of SRG3 protein in the transfected cells, there still remained
50% (clone A) or 30% (clone B) of normal level of SRG3 protein (Fig. 6). Even in the case of the clone B transfectant, this is at least the similar level of protein found in peripheral T lymphocytes (Fig. 3). Therefore, it is likely that there still may be enough SRG3 protein left to form SWI–SNF complexes in the transfectants. These results suggest a possibility that SRG3 protein may function independently of the SWI– SNF complex in GC-mediated apoptosis. No matter how SRG3 functions in GC-mediated apoptosis in thymoma cells, either as a component of SWI–SNF complex or as an independent factor of the complex, our present results show that SRG3 protein is required for the process and possibly plays an important regulatory role during thymocyte development.
| Acknowledgments |
|---|
This work was supported in part by the S.N.U.-Daewoo Research Fund (94-06-2068, 96-06-2078) and the Biotech 2000 project to R.H. Seong, and in part by grants from the Korea Science and Engineering Foundation, through the Research Center for Cell Differentiation, to S.D. Park and R.H. Seong.
Submitted: 22 January 1997
Revised: 17 March 1997
| References |
|---|
|
|
|---|
1 von Boehmer H, Teh HS & Kisielow P. The thymus selects the useful, neglects the useless and destroys the harmful, Immunol Today, 1989, 10, 57–60.[Medline]
2 Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation, Nature (Lond), 1980, 284, 555–556.[Medline]
3 Cohen JJ & Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death, J Immunol, 1984, 132, 38–42.[Abstract]
4 Compton MM & Cidlowski JA. Thymocyte apoptosis. A model of programmed cell death, TEM, 1992, 3, 17–23.[Medline]
5 Nieto M, Gonzalez A, Lopez A, Rivas, Diaz-Espada K & Gambon F. IL-2 protects against anti-CD3–induced cell death in human medullary thymocytes, J Immunol, 1990, 145, 1364–1368.[Abstract]
6 Williams G, Smith C, Spooncer E, Dexter T & Taylor D. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis, Nature (Lond), 1990, 343, 76–79.[Medline]
7 Sellins KS & Cohen JJ. Gene induction by
-irradiation leads to DNA fragmentation in lymphocytes, J Immunol, 1987, 139, 3199–3206.[Abstract]
8 McConkey DJ, Hartzell P, Amador-Pérez JF, Orrenius S & Jondal M. Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex, J Immunol, 1989, 143, 1801–1806.[Abstract]
9 Smith CA, Williams GT, Kingston R, Jenkinson EJ & Owen JJT. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures, Nature (Lond), 1989, 337, 181–184.[Medline]
10 Shi Y, Bissonnette RP, Parfrey N, Szalay M, Kubo RT & Green DR. In vivo administration of monoclonal antibodies to the CD3 T cell receptor complex induces cell death (apoptosis) in immature thymocytes, J Immunol, 1991, 146, 3340–3346.[Abstract]
11 Jondal, M., Y. Xue, D.J. McConkey, and S. Okret. 1995. Thymocyte apoptosis by glucocorticoids and cAMP. In Apoptosis in immunology. G. Kroemer and C. Martinez-A., editors. Springer-Verlag, Berlin. 67–79.
12 Vacchio MS, Papadopoulos V & Ashwell JD. Steroid production in the thymus: implications for thymocyte selection, J Exp Med, 1994, 179, 1835–1846.
13 King LB, Vacchio MS, Dixon K, Hunziker R, Margulies DH & Ashwell JD. A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development, Immunity, 1995, 3, 647–656.[Medline]
14 Zacharchuk CM, Mercep M, Chakraborti P, Simons SS Jr & Ashwell JD. Programmed T lymphocyte death: cell activation- and steroid-induced pathways are mutually antagonistic, J Immunol, 1990, 145, 4037–4045.[Abstract]
15 Iwata M, Hanaoka S & Sato K. Rescue of thymocytes and T cell hybridomas from glucocorticoid-induced apoptosis by stimulation via the T cell receptor/CD3 complex: a possible in vitromodel for positive selection of the T cell repertoire, Eur J Immunol, 1991, 21, 643–648.[Medline]
16 Schüle R, Muller M, Kaltschmidt C & Renkawitz R. Many transcription factors interact synergistically with steroid receptors, Science (Wash DC), 1988, 242, 1418–1420.
17 Strähle U, Schmid W & Schütz G. Synergistic action of the glucocorticoid receptor with transcription factors, EMBO (Eur Mol Biol Organ) J, 1988, 7, 3389–3395.[Medline]
18 Imai E, Miner JN, Mitchell JA, Yamamoto KR & Granner DK. Glucocorticoid receptor–cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids, J Biol Chem, 1993, 268, 5353–5356.
19 Yoshinaga SK, Peterson CL, Herskowitz I & Yamamoto KR. Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors, Science (Wash DC), 1992, 258, 1598–1604.
20 Muchardt C & Yaniv M. A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brmgenes potentiates transcriptional activation by the glucocorticoid receptor, EMBO (Eur Mol Biol Organ) J, 1993, 12, 4279–4290.[Medline]
21 Kruger W & Herskowitz I. A negative regulator of HOtranscription, SIN1 (SPT2), is a nonspecific DNA-binding protein related to HMG1, Mol Cell Biol, 1991, 11, 4135–4146.
22 Hirschhorn JN, Brown SA, Clark CD & Winston F. Evidence that SNF2/SWI2 and SNF5 activate transcription in yeast by altering chromatin structure, Genes Dev, 1992, 6, 2228–2298.
23 Peterson CL & Tamkun JW. The SWI-SNF complex: a chromatin remodeling machine? , TIBS, 1995, 20, 143–146.[Medline]
24 Stern M, Jensen R & Herskowitz I. Five SWI genes are required for expression of the HOgene in yeast, J Mol Biol, 1984, 178, 853–868.[Medline]
25 Sternberg PW, Stern MJ, Clark I & Herskowitz I. Activation of the yeast HOgene by release from multiple negative controls, Cell, 1987, 48, 567–577.[Medline]
26 Carlson M, Osmond BC & Botstein D. Mutants of yeast defective in sucrose utilization, Genetics, 1981, 98, 25–40.
27 Neigeborn L & Carlson M. Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. , Genetics, 1984, 108, 845–858.
28 Estruch F & Carlson M. SNF6 encodes a nuclear protein that is required for expression of many genes in Saccharomyces cerevisiae. , Mol Cell Biol, 1990, 10, 2544–2553.
29 Laurent BC, Treitel MA & Carlson M. The SNF5 protein of Saccharomyces cerevisiaeis a glutamine- and proline-rich transcriptional activator that affects expression of a broad spectrum of genes, Mol Cell Biol, 1990, 10, 5616–5625.
30 Happel AM, Swanson MS & Winston F. The SNF2, SNF5 and SNF6 genes are required for Ty transcription in Saccharomyces cerevisiae. , Genetics, 1991, 128, 69–77.[Abstract]
31 Côté J, Quinn J, Workman L & Peterson CL. Stimulation of GAL4 derivative binding to nucleosomal DNA by the yeast SWI/SNF complex, Science (Wash DC), 1994, 265, 53–60.
32 Laurent BC, Treitel MA & Carlson M. Functional interdependence of the yeast SNF2, SNF5, and SNF6proteins in transcriptional activation, Proc Natl Acad Sci USA, 1991, 88, 2687–2691.
33 Peterson CL & Herskowitz I. Characterization of the yeast SWI1, SWI2, SWI3genes, which encode a global activator of transcription, Cell, 1992, 68, 573–583.[Medline]
34 Cairns BR, Kim Y-J, Sayre MH, Laurent BC & Kornberg RD. A multisubunit complex containing the SWI1/ADR6, SWI2/SNF2, SWI3, SNF5, and SNF6 gene products isolated from yeast, Proc Natl Acad Sci USA, 1994, 91, 1950–1954.
35 Peterson CL, Dingwall A & Scott MP. Five SWI/SNFgene products are components of a large multisubunit complex required for transcriptional enhancement, Proc Natl Acad Sci USA, 1994, 91, 2905–2908.
36 Okabe I, Bailey LC, Attree O, Srinivasan S, Perkel JM, Laurent BC, Carlson M, Nelson DL & Nussbaum RL. Cloning of human and bovine homologs of SNF2/ SWI2: a global activator of transcription in yeast S. cerevisiae. , Nucleic Acids Res, 1992, 20, 4649–4655.
37 Tamkun JW, Deuring R, Scott MP, Kissinger M, Pattatucci AM, Kaufman TC & Kennison JA. brahma: A regulator of Drosophilahomeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2, Cell, 1992, 68, 561–572.[Medline]
38 Khavari PA, Peterson CL, Tamkun JW, Mendel DB & Crabtree GR. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription, Nature (Lond), 1993, 366, 170–174.[Medline]
39 Chiba H, Muramatsu M, Nomoto A & Kato H. Two human homologues of Saccharomyces cerevisiae SNF2/ SWI2 and Drosophilabrahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor, Nucleic Acids Res, 1994, 22, 1815–1820.
40 Muchardt C, Sardet C, Bourachot B, Onufryk C & Yaniv M. A human protein homology to Saccharomyces cerevisiaeSNF5 interacts with the potential helicase hbrm, Nucleic Acids Res, 1995, 23, 1127–1132.
41 Kalpana GV, Marmon S, Wang W, Crabtree GR & Goff SP. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5, Science (Wash DC), 1994, 266, 2002–2006.
42 Wang W, Xue Y, Zhou S, Kuo A, Cairns BR & Crabtree GR. Diversity and specialization of mammalian SWI/SNF complexes, Genes Dev, 1996, 10, 2117–2130.
43 Kwon H, Imbalzano AN, Khavari PA, Kingston RE & Green MR. Nucleosome disruption and enhancement of activator binding by a human SWI/SNF complex, Nature (Lond), 1994, 370, 477–481.[Medline]
44 Chomczynski P & Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol– chloroform extraction, Anal Biochem, 1987, 162, 156–159.[Medline]
45 Aviv H & Leader P. Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid–cellulose, Proc Natl Acad Sci USA, 1972, 69, 1408–1412.
46 Rodriguez IR & Chader GJ. A novel method for the isolation of tissue-specific genes, Nucleic Acids Res, 1992, 20, 3528, .
47 Sanger F, Nicklen S & Coulson AR. DNA sequencing with chain terminating inhibitors, Proc Natl Acad Sci USA, 1977, 74, 5463–5467.
48 Altschul SF, Gish W, Miller W, Myers EW & Lipman DJ. Basic local alignment search tools, J Mol Biol, 1990, 215, 403–410.[Medline]
49 Miltenyi S, Müller W, Weichel W & Radbruch A. High gradient magnetic cell separation with MACS, Cytometry, 1990, 11, 231–238.[Medline]
50 Smith DB & Johnson KS. Single-step purification of polypeptides expressed in Escherichia colias fusion with glutathione-S-transferase, Gene, 1988, 67, 31–40.[Medline]
51 Breeden L & Nasmyth K. Cell cycle control of the yeast HOgene: cis- and trans-acting regulators, Cell, 1987, 48, 389–397.[Medline]
52 Nicoletti I, Migliorati G, Pagliacci MC, Grignani F & Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry, J Immunol Methods, 1991, 139, 271–279.[Medline]
53 Landschulz WH, Johnson PF & Mcknight SL. The leucine zipper, a hypothetical structure common to a new class of DNA binding proteins, Science (Wash DC), 1988, 240, 1759–1764.
54 Aasland R. The SANT domain: a putative DNAbinding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB, TIBS, 1996, 21, 87–88.[Medline]
55 van de Wetering M, Oosterwegel M, Dooijes D & Clevers H. Identification and cloning of TCF-1, a T lymphocyte–specific transcription factor containing a sequencespecific HMG box, EMBO (Eur Mol Biol Organ) J, 1991, 10, 123–132.[Medline]
56 Verbeek S, Izon D, Hofhuls F, Robanus-Maandag E, Riele H, van de Wetering M, Oosterwegel M, Wilson A, MacDonald HR & Clevers H. An HMG-box–containing T-cell factor required for thymocyte differentiation, Nature (Lond), 1995, 374, 70–74.[Medline]
57 Schena M & Yamamoto KR. Mammalian glucocorticoid receptor derivatives enhance transcription in yeast, Science (Wash DC), 1988, 241, 965–967.
58 Schena M, Freedman LP & Yamamoto KR. Mutations in the glucocorticoid receptor zinc finger region that distinguish interdigitated DNA binding and transcriptional enhancement activities, Genes Dev, 1989, 3, 1590–1601.
59 Cairns BR, Levinson RS, Yamamoto KR & Kornberg RD. Essential role of Swp73p in the function of yeast Swi/Snf complex, Genes Dev, 1996, 10, 2131–2144.
60 Gonzalo JA, Gonzàlez-Garcia A & Martìnez C. -A, and G. Kroemer. Glucocorticoid mediated control of the activation and clonal deletion of peripheral T cells in vivo. , J Exp Med, 1993, 177, 1239–1246.
61 Jondal M, Okret S & McConkey D. Killing of immature CD4+CD8+ thymocytes in vivoby anti-CD3 or 5'-(N-ethyl)-carboxamide adenosine is blocked by glucocorticoid receptor antagonist RU-486, Eur J Immunol, 1993, 23, 1246–1250.[Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|